Guoqing Wei

5.8k total citations · 1 hit paper
69 papers, 2.3k citations indexed

About

Guoqing Wei is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Guoqing Wei has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 16 papers in Molecular Biology and 15 papers in Hematology. Recurrent topics in Guoqing Wei's work include CAR-T cell therapy research (42 papers), Virus-based gene therapy research (13 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Guoqing Wei is often cited by papers focused on CAR-T cell therapy research (42 papers), Virus-based gene therapy research (13 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Guoqing Wei collaborates with scholars based in China, United States and Israel. Guoqing Wei's co-authors include Delong Liu, Kemeng Wang, He Huang, Shamudheen Mohammed Rafiyath, Byung Moo Lee, Mohammed Fatih Rasul, Gurpreet Lamba, Yongxian Hu, Wenjun Wu and Hongliu Cai and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Guoqing Wei

64 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

2021 202 citations Yongxian Hu, Yali Zhou et al. Clinical Cancer Research profile →

Peers

Guoqing Wei

ONCOL

IMMUN

HEMAT

Yozo Nakazawa Japan

Ravindra Kolhe United States

Hua Song China

Ling Xu China

Rainer Wiewrodt Germany

Sa Wang China

Hans Schlößer Germany

F. Schlemmer France

Jing Chen China

Shuang Qin China

Yozo Nakazawa Japan

Guoqing Wei

923 ×0.8

ONCOL

875 ×1.2

792 ×2.1

IMMUN

595 ×1.8

HEMAT

262 ×0.8

Citations per year, relative to Guoqing Wei Guoqing Wei (= 1×) peers Yozo Nakazawa

Countries citing papers authored by Guoqing Wei

Since Specialization

Citations

This map shows the geographic impact of Guoqing Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guoqing Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guoqing Wei more than expected).

Fields of papers citing papers by Guoqing Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guoqing Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guoqing Wei. The network helps show where Guoqing Wei may publish in the future.

Co-authorship network of co-authors of Guoqing Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Guoqing Wei. A scholar is included among the top collaborators of Guoqing Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guoqing Wei. Guoqing Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Yongxian, Jiqin Zhang, Mingming Zhang, et al.. (2024). Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7031–7031. 1 indexed citations

Huang, He, Yongxian Hu, Guoqing Wei, et al.. (2024). OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).. Journal of Clinical Oncology. 42(16_suppl). 7511–7511. 7 indexed citations

Zhang, Mingming, Yongxian Hu, Guoqing Wei, et al.. (2024). Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma. Blood. 144(Supplement 1). 91–91. 1 indexed citations

Zhang, Mingming, Guoqing Wei, Linghui Zhou, et al.. (2023). GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology. 10(2). e107–e116. 91 indexed citations

Hu, Yongxian, Fang Ni, Zhongli Yang, et al.. (2022). CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nature Communications. 13(1). 5313–5313. 90 indexed citations

Wei, Guoqing, et al.. (2022). Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse. Journal of Zhejiang University (Medical Sciences). 51(2). 151–159. 1 indexed citations

Lü, Wenjing, et al.. (2022). A comparative analysis of photosynthetic function and reactive oxygen species metabolism responses in two hibiscus cultivars under saline conditions. Plant Physiology and Biochemistry. 184. 87–97. 14 indexed citations

Wang, Linqin, Ruimin Hong, Linghui Zhou, et al.. (2022). Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor–T-cell therapy. Cytotherapy. 25(2). 192–201. 6 indexed citations

Yang, Tingting, Delin Kong, Guoqing Wei, et al.. (2022). Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy. Frontiers in Immunology. 13. 934442–934442. 1 indexed citations

10.

Wei, Guoqing, Yanlei Zhang, Houli Zhao, et al.. (2021). CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research. 9(9). 1061–1070. 47 indexed citations

11.

Hu, Yongxian, Yali Zhou, Mingming Zhang, et al.. (2021). CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 27(10). 2764–2772. 202 indexed citations breakdown →

12.

Shao, Mi, Qin Yu, Xinyi Teng, et al.. (2021). CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplantation. 56(7). 1642–1650. 24 indexed citations

13.

Wang, Yiyun, Linqin Wang, Yifan Zeng, et al.. (2021). Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission. Frontiers in Oncology. 11. 755584–755584. 6 indexed citations

14.

Liang, Bin, Yan Liu, Guoqing Wei, et al.. (2021). Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. Frontiers in Pharmacology. 12. 702152–702152. 3 indexed citations

15.

Hong, Ruimin, Houli Zhao, Yiyun Wang, et al.. (2020). Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation. 56(3). 570–580. 28 indexed citations

16.

Jin, Aiyun, Jingjing Feng, Guoqing Wei, et al.. (2020). CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. Bone Marrow Transplantation. 55(4). 717–721. 7 indexed citations

17.

Wei, Guoqing, et al.. (2020). Weathering the storm: COVID-19 infection in patients with hematological malignancies. Journal of Zhejiang University SCIENCE B. 21(12). 921–939. 2 indexed citations

18.

Hu, Yongxian, Jiasheng Wang, Chengfei Pu, et al.. (2018). Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Research and Treatment. 50(4). 1462–1466. 10 indexed citations

19.

Wei, Guoqing, et al.. (2012). Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Experimental Hematology and Oncology. 1(1). 3–3. 13 indexed citations

20.

Ma, Songde, et al.. (1993). Segment based camera calibration. Journal of Computer Science and Technology. 8(1). 11–16. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact